应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
BL Blackline Inc.
休市中 10-16 16:00:00 EDT
29.80
-0.71
-2.33%
盘后
29.80
+0.00
0.00%
19:30 EDT
最高
30.94
最低
29.25
成交量
64.37万
今开
30.71
昨收
30.51
日振幅
5.56%
总市值
17.32亿
流通市值
13.14亿
总股本
5,813万
成交额
1,915万
换手率
1.46%
流通股本
4,410万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
Blackline收购Netnow，以智能客户入驻与信用风险管理拓展发票至现金流程
美股速递 · 09-21
Blackline收购Netnow，以智能客户入驻与信用风险管理拓展发票至现金流程
百利天恒：注射用BL-M14D1联合免疫治疗一线SCLC全球III期临床完成首例给药
智通财经 · 08-06
百利天恒：注射用BL-M14D1联合免疫治疗一线SCLC全球III期临床完成首例给药
财报前瞻｜BlackLine Inc.本季度营收预计增9.48%，机构观点偏谨慎
财报Agent · 07-29
财报前瞻｜BlackLine Inc.本季度营收预计增9.48%，机构观点偏谨慎
百利天恒(688506.SH)：BL-M14D1(DLL3ADC)联合免疫治疗用于一线广泛期小细胞肺癌患者的III期临床试验申请获得FDA许可
智通财经网 · 06-08
百利天恒(688506.SH)：BL-M14D1(DLL3ADC)联合免疫治疗用于一线广泛期小细胞肺癌患者的III期临床试验申请获得FDA许可
依托成熟毒素平台 百利天恒BL-M05D1胃癌III期试验完成首例入组
财中社 · 06-04
依托成熟毒素平台 百利天恒BL-M05D1胃癌III期试验完成首例入组
百利天恒：注射用BL-M08D1获临床试验批准
南方财经网 · 06-04
百利天恒：注射用BL-M08D1获临床试验批准
财报前瞻｜Blackline Inc.本季度营收预计增8.60%，机构观点偏乐观
财报Agent · 04-28
财报前瞻｜Blackline Inc.本季度营收预计增8.60%，机构观点偏乐观
【百利天恒：BL-B01D1（EGFR×HER3 双抗 ADC）联合奥希替尼用于一线 EGFR 突变型局部晚期或转移性非小细胞肺癌 III 期临床试验完成首例受试者入组】金融界3月2日消息，百利天恒自主研发的创新生物药注射用 BL-B01D1（EGFR×HER3 双抗 ADC）联合奥希替尼用于一线 EGFR 突变型局部晚期或转移性非小细胞肺癌的 III 期临床试验已于近日完成首例受试者入组。BL-B01D1 是全球独家处于 III 期注册临床试验阶段的可同时靶向 EGFR 和 HER3 的双抗 ADC 药物。截至目前，BL-B01D1 正在中国和美国进行约 30 项针对多种肿瘤类型的临床试验，除本次新入组的临床试验外，其在肺癌、乳腺癌、鼻咽癌、食管鳞癌等 7 项国内 III 期注册临床试验也处于受试者入组阶段。药品需完成临床试验并通过审评审批方可上市销售，且医药产品具有高科技、高风险等特点，容易受到不确定性因素影响。
金融界 · 2025-03-02
【百利天恒：BL-B01D1（EGFR×HER3 双抗 ADC）联合奥希替尼用于一线 EGFR 突变型局部晚期或转移性非小细胞肺癌 III 期临床试验完成首例受试者入组】金融界3月2日消息，百利天恒自主研发的创新生物药注射用 BL-B01D1（EGFR×HER3 双抗 ADC）联合奥希替尼用于一线 EGFR 突变型局部晚期或转移性非小细胞肺癌的 III 期临床试验已于近日完成首例受试者入组。BL-B01D1 是全球独家处于 III 期注册临床试验阶段的可同时靶向 EGFR 和 HER3 的双抗 ADC 药物。截至目前，BL-B01D1 正在中国和美国进行约 30 项针对多种肿瘤类型的临床试验，除本次新入组的临床试验外，其在肺癌、乳腺癌、鼻咽癌、食管鳞癌等 7 项国内 III 期注册临床试验也处于受试者入组阶段。药品需完成临床试验并通过审评审批方可上市销售，且医药产品具有高科技、高风险等特点，容易受到不确定性因素影响。
百利天恒(688506.SH)注射用BL-M07D1(HER2-ADC)获II/III期临床试验批准通知书
智通财经 · 2025-02-18
百利天恒(688506.SH)注射用BL-M07D1(HER2-ADC)获II/III期临床试验批准通知书
Blackline, Inc.2024财年实现净利润1.61亿美元，同比增加204.75%
市场透视 · 2025-02-16
Blackline, Inc.2024财年实现净利润1.61亿美元，同比增加204.75%
Blackline, Inc.股价重挫14.28% 市值跌4.85亿美元
市场透视 · 2025-02-12
Blackline, Inc.股价重挫14.28% 市值跌4.85亿美元
BlackLine第四季度调整后的每股收益为$0.47，低于预期的$0.50，销售额为$1.6946亿，高于预期的$1.6834亿
财报速递 · 2025-02-12
BlackLine第四季度调整后的每股收益为$0.47，低于预期的$0.50，销售额为$1.6946亿，高于预期的$1.6834亿
百利天恒(688506.SH)：注射用BL-M07D1(HER2-ADC)III期临床试验获批准
智通财经 · 2025-02-07
百利天恒(688506.SH)：注射用BL-M07D1(HER2-ADC)III期临床试验获批准
Blackline, Inc.盘中异动 早盘股价大涨5.34%
市场透视 · 2025-01-30
Blackline, Inc.盘中异动 早盘股价大涨5.34%
B of A Securities：上调BlackLine(BL.US)评级，由低于大市调整至买入评级, 目标价由50.00美元调整至75.00美元。
金融界 · 2025-01-30
B of A Securities：上调BlackLine(BL.US)评级，由低于大市调整至买入评级, 目标价由50.00美元调整至75.00美元。
Blackline, Inc.盘中异动 下午盘股价大涨5.01%报64.81美元
市场透视 · 2025-01-29
Blackline, Inc.盘中异动 下午盘股价大涨5.01%报64.81美元
Blackline, Inc.盘中异动 股价大跌5.05%
市场透视 · 2025-01-07
Blackline, Inc.盘中异动 股价大跌5.05%
百利天恒(688506.SH)：注射用BL-B01D1被药审中心纳入突破性治疗品种名单
智通财经 · 2025-01-02
百利天恒(688506.SH)：注射用BL-B01D1被药审中心纳入突破性治疗品种名单
百利天恒(688506.SH)：BL-M08D1(ADC)临床试验申请获得批准
智通财经 · 2024-11-28
百利天恒(688506.SH)：BL-M08D1(ADC)临床试验申请获得批准
Blackline, Inc.2024财年第三财季实现净利润17.24百万美元，同比增加44.63%
市场透视 · 2024-11-17
Blackline, Inc.2024财年第三财季实现净利润17.24百万美元，同比增加44.63%
加载更多
公司概况
公司名称：
Blackline Inc.
所属市场：
NASDAQ
上市日期：
--
主营业务：
BlackLine, Inc.以BlackLine Systems, Inc之名成立于2001年5月。该公司已经创建了一个全面的基于云计算的软件平台，旨在为所有类型和规模的组织变革和现代化的会计和财务运作。他们的安全可扩展的平台支持关键会计流程，如财务结算，对账，公司间的会计和控制的保证等。通过引入软件来自动化这些流程并使其能够持续运行，他们授权客户提高其财务报告的完整性，提高效率并增强其运营的实时可见性。
发行价格：
--
{"stockData":{"symbol":"BL","market":"US","secType":"STK","nameCN":"Blackline Inc.","latestPrice":29.8,"timestamp":1792180800000,"preClose":30.51,"halted":0,"volume":643651,"hourTrading":{"tag":"盘后","latestPrice":29.8,"preClose":29.8,"latestTime":"19:30 EDT","volume":20459,"amount":609678.2,"timestamp":1792193404147,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.023271058669288785,"floatShares":44099200,"shares":58125270,"eps":0.562917,"marketStatus":"休市中","change":-0.71,"latestTime":"10-16 16:00:00 EDT","open":30.71,"high":30.94,"low":29.245,"amount":19154805.954365,"amplitude":0.055556,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.562917,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1792396800000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1477627200000,"exchange":"NASDAQ","adjPreClose":30.51,"preHourTrading":{"tag":"盘前","latestPrice":30.7,"preClose":30.51,"latestTime":"09:29 EDT","volume":1842,"amount":56179.207734,"timestamp":1792157399982,"change":0.19,"changeRate":0.006227,"amplitude":0.08194},"postHourTrading":{"tag":"盘后","latestPrice":29.8,"preClose":29.8,"latestTime":"19:30 EDT","volume":20459,"amount":609678.2,"timestamp":1792193404147,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.7435729245311995,"impliedVol":0.7111,"impliedVolPercentile":0.6733},"requestUrl":"/m/hq/s/BL","defaultTab":"news","newsList":[{"id":"1107733014","title":"Blackline收购Netnow，以智能客户入驻与信用风险管理拓展发票至现金流程","url":"https://stock-news.laohu8.com/highlight/detail?id=1107733014","media":"美股速递","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1107733014?lang=zh_cn&edition=full","pubTime":"2026-09-21 20:30","pubTimestamp":1789993835,"startTime":"0","endTime":"0","summary":"Blackline宣布收购Netnow，此举将进一步扩展其在发票到现金管理领域的版图，重点强化智能客户入驻流程与信用风险管控能力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1815336091.USD","LU0757428866.USD","BL","BK4023"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657895786","title":"百利天恒：注射用BL-M14D1联合免疫治疗一线SCLC全球III期临床完成首例给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2657895786","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657895786?lang=zh_cn&edition=full","pubTime":"2026-08-06 17:04","pubTimestamp":1786007078,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU1815336091.USD","III","LU0757428866.USD","BK4134","BL","BK4023"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141125379","title":"财报前瞻｜BlackLine Inc.本季度营收预计增9.48%，机构观点偏谨慎","url":"https://stock-news.laohu8.com/highlight/detail?id=1141125379","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1141125379?lang=zh_cn&edition=full","pubTime":"2026-07-29 03:58","pubTimestamp":1785268687,"startTime":"0","endTime":"0","summary":"BlackLine Inc.将于2026年08月04日发布最新季度财报，市场关注订阅与AI产品推进对收入与盈利弹性的影响。市场一致预期BlackLine Inc.本季度营收为1.87亿美元，同比增长9.48%；调整后每股收益为0.57美元，同比增长12.57%；息税前利润为4,140.40万美元，同比增长15.27%。上季度公司营收为1.83亿美元，同比增长9.72%；毛利率为75.97%；归属于母公司股东的净利润为812.60万美元，净利率为4.44%；调整后每股收益为0.56美元，同比增长14.29%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"财报前瞻｜BlackLine Inc.本季度营收预计增9.48%，机构观点偏谨慎","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641045171","title":"百利天恒(688506.SH)：BL-M14D1(DLL3ADC)联合免疫治疗用于一线广泛期小细胞肺癌患者的III期临床试验申请获得FDA许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2641045171","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2641045171?lang=zh_cn&edition=full","pubTime":"2026-06-08 15:36","pubTimestamp":1780904174,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百利天恒 发布公告，公司的全资子公司 SystImmune,Inc.近日收到美国食品药品监督管理局的通知， BL-M14D1联合免疫治疗用于一线广泛期小细胞肺癌患者的III期临床试验申请已获得FDA许可。BL-M14D1与iza-bren 共享同一小分子技术平台，公司拥有其完整的全球权益。本次BL-M14D1的III期临床研究获得FDA的IND许可，将进一步推进公司业务和产品国际化布局的进程，对公司近期业绩不会产生重大影响。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1451325.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK4023","LU0757428866.USD","BK4134","688506","BK4588","LABU","91194","BL","02615","BK0239","III","BK4585","LU1815336091.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640197152","title":"依托成熟毒素平台 百利天恒BL-M05D1胃癌III期试验完成首例入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2640197152","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2640197152?lang=zh_cn&edition=full","pubTime":"2026-06-04 19:52","pubTimestamp":1780573920,"startTime":"0","endTime":"0","summary":"6月4日，百利天恒（688506）发布公告，公司自主研发的创新生物药注射用BL-M05D1（Claudin18.2ADC）用于在既往经一线治疗的Claudin18.2阳性晚期胃癌或胃食管结合部腺癌的III期临床试验已完成首例受试者入组。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202606043760581427.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606043760581427.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4023","LU0757428866.USD","BK4134","688506","91194","BL","02615","BK0239","III","LU1815336091.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640154692","title":"百利天恒：注射用BL-M08D1获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2640154692","media":"南方财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2640154692?lang=zh_cn&edition=full","pubTime":"2026-06-04 18:54","pubTimestamp":1780570440,"startTime":"0","endTime":"0","summary":"南财智讯6月4日电，百利天恒公告，百利天恒（简称）收到国家药品监督管理局正式批准签发的《药物临床试验批准通知书》。公司自主研发的创新生物药注射用BL-M08D1（ADC）联合用药的临床试验获得批准，适应症为弥漫大B细胞淋巴瘤。该药物与iza-bren出自同一技术平台，共享同一“连接子+毒素”平台。公司将按规定积极推进研发项目，并及时履行后续信息披露义务。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202606043760550358.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606043760550358.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0757428866.USD","LU1815336091.USD","BK0239","688506","BK4023","02615","91194","BL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167587485","title":"财报前瞻｜Blackline Inc.本季度营收预计增8.60%，机构观点偏乐观","url":"https://stock-news.laohu8.com/highlight/detail?id=1167587485","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1167587485?lang=zh_cn&edition=full","pubTime":"2026-04-28 14:31","pubTimestamp":1777357911,"startTime":"0","endTime":"0","summary":"Blackline Inc.将于2026年05月05日盘后披露财报，市场关注订阅收入带动的稳健增长与利润率修复路径。市场一致预期本季度Blackline Inc.收入为1.81亿美元，同比增长8.60%；调整后每股收益为0.45美元，同比增长17.25%；息税前利润为3,433.01万美元，同比增长20.03%。上季度Blackline Inc.实现收入1.83亿美元，同比增长8.10%；毛利率为75.19%；归属于母公司股东的净利润为488.60万美元，净利率2.67%；调整后每股收益为0.63美元，同比增长34.04%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜Blackline Inc.本季度营收预计增8.60%，机构观点偏乐观","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516364590","title":"【百利天恒：BL-B01D1（EGFR×HER3 双抗 ADC）联合奥希替尼用于一线 EGFR 突变型局部晚期或转移性非小细胞肺癌 III 期临床试验完成首例受试者入组】金融界3月2日消息，百利天恒自主研发的创新生物药注射用 BL-B01D1（EGFR×HER3 双抗 ADC）联合奥希替尼用于一线 EGFR 突变型局部晚期或转移性非小细胞肺癌的 III 期临床试验已于近日完成首例受试者入组。BL-B01D1 是全球独家处于 III 期注册临床试验阶段的可同时靶向 EGFR 和 HER3 的双抗 ADC 药物。截至目前，BL-B01D1 正在中国和美国进行约 30 项针对多种肿瘤类型的临床试验，除本次新入组的临床试验外，其在肺癌、乳腺癌、鼻咽癌、食管鳞癌等 7 项国内 III 期注册临床试验也处于受试者入组阶段。药品需完成临床试验并通过审评审批方可上市销售，且医药产品具有高科技、高风险等特点，容易受到不确定性因素影响。","url":"https://stock-news.laohu8.com/highlight/detail?id=2516364590","media":"金融界","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516364590?lang=zh_cn&edition=full","pubTime":"2025-03-02 15:34","pubTimestamp":1740900843,"startTime":"0","endTime":"0","summary":"金融界3月2日消息，百利天恒自主研发的创新生物药注射用 BL-B01D1 联合奥希替尼用于一线 EGFR 突变型局部晚期或转移性非小细胞肺癌的 III 期临床试验已于近日完成首例受试者入组。BL-B01D1 是全球独家处于 III 期注册临床试验阶段的可同时靶向 EGFR 和 HER3 的双抗 ADC 药物。截至目前，BL-B01D1 正在中国和美国进行约 30 项针对多种肿瘤类型的临床试验，除本次新入组的临床试验外，其在肺癌、乳腺癌、鼻咽癌、食管鳞癌等 7 项国内 III 期注册临床试验也处于受试者入组阶段。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/02153448475153.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BL","159938","BK1574","BK1515","BK4080","BK1161","BK4231","LU0757428866.USD","III","ADC","09939","BK4023","159839","BK1576","LU1815336091.USD","BK0239","BK1141","BK1583","03347","688506","BK4134"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512163139","title":"百利天恒(688506.SH)注射用BL-M07D1(HER2-ADC)获II/III期临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2512163139","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2512163139?lang=zh_cn&edition=full","pubTime":"2025-02-18 17:04","pubTimestamp":1739869479,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百利天恒 公告，公司于近日收到国家药品监督管理局正式批准签发的《药物临床试验批准通知书》,公司自主研发的创新生物药注射用BL-M07D1的II/III期临床试验获得批准。据悉，BL-M07D1是一种靶向HER2的创新ADC，具有best-in-class潜力，已在临床试验中展示出显著的抗肿瘤功效。截至本公告披露日，除本次新获得批准的临床试验外，BL-M07D1正于中国及美国的10项I/II/III期临床试验中作为单药或联用进行评估。各项临床研究包括各种HER2表达/突变的实体瘤的患者。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1251148.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["ADC","BK4023","BK4231","BK4080","BK0239","688506","03347","BK1576","III","LU1815336091.USD","BK4134","LU0757428866.USD","BK1141","BK1583","BL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2511670288","title":"Blackline, Inc.2024财年实现净利润1.61亿美元，同比增加204.75%","url":"https://stock-news.laohu8.com/highlight/detail?id=2511670288","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2511670288?lang=zh_cn&edition=full","pubTime":"2025-02-16 00:00","pubTimestamp":1739635247,"startTime":"0","endTime":"0","summary":"2月16日，Blackline, Inc.公布财报，公告显示公司2024财年净利润为1.61亿美元，同比增加204.75%；其中营业收入为6.53亿美元，同比增加10.68%，每股基本收益为2.59美元。从资产负债表来看，Blackline, Inc.总负债13.42亿美元，其中短期债务3.59百万美元，资产负债比为1.36，流动比率为2.59。机构评级：截至2025年2月16日，当前有10家机构对Blackline, Inc.目标价做出预测，其中目标均价为64.80美元，其中最低目标价为51.00美元，最高目标价为80.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250216000102a24729b7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250216000102a24729b7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2510034123","title":"Blackline, Inc.股价重挫14.28% 市值跌4.85亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2510034123","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2510034123?lang=zh_cn&edition=full","pubTime":"2025-02-12 22:32","pubTimestamp":1739370722,"startTime":"0","endTime":"0","summary":"北京时间2025年02月12日22时32分，Blackline, Inc.股票出现波动，股价快速下挫14.28%。截至发稿，该股报54.35美元/股，成交量11.2069万股，换手率0.18%，振幅1.37%。Blackline, Inc.股票所在的软件服务行业中，整体跌幅为1.21%。Blackline, Inc.公司简介：BlackLine Inc 致力于提供以软件即服务 形式交付的财务会计结算解决方案。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250212223202abcc5d49&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250212223202abcc5d49&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BL","BK4023","LU1815336091.USD","LU0757428866.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135492876","title":"BlackLine第四季度调整后的每股收益为$0.47，低于预期的$0.50，销售额为$1.6946亿，高于预期的$1.6834亿","url":"https://stock-news.laohu8.com/highlight/detail?id=1135492876","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1135492876?lang=zh_cn&edition=full","pubTime":"2025-02-12 05:12","pubTimestamp":1739308378,"startTime":"0","endTime":"0","summary":"BlackLine 报告的季度每股收益为$0.47，比分析师预期的$0.50低了6%。这比去年同期每股收益$0.69下降了31.88%。公司报告的季度销售额为$1.6946亿，超过了分析师预期的$1.6834亿，高出了0.66%。这比去年同期的$1.5573亿增长了8.82%。以上内容来自Benzinga Earnings专栏，原文如下：BlackLine reported quarterly earnings of $0.47 per share which missed the analyst consensus estimate of $0.50 by 6 percent. This is a 31.88 percent decrease over earnings of $0.69 per share from the same period last year. The company reported quarterly sales of $169.46 million which beat the analyst consensus estimate of $168","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"BlackLine第四季度调整后的每股收益为$0.47，低于预期的$0.50，销售额为$1.6946亿，高于预期的$1.6834亿","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509799007","title":"百利天恒(688506.SH)：注射用BL-M07D1(HER2-ADC)III期临床试验获批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2509799007","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2509799007?lang=zh_cn&edition=full","pubTime":"2025-02-07 16:34","pubTimestamp":1738917290,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百利天恒(688506.SH)发布公告，公司于近日收到国家药品监督管理局(NMPA)正式批准签发的《药物临床试验批准通知书》,公司自主研发的创新生物药注射用BL-M07D1(HER2-ADC)的III期临床试验获得批准。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1247092.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688506","BK4080","LU0757428866.USD","BK1576","BL","III","LU1815336091.USD","BK1583","BK4023","ADC","BK0239","BK4134","BK4231","03347","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2507362189","title":"Blackline, Inc.盘中异动 早盘股价大涨5.34%","url":"https://stock-news.laohu8.com/highlight/detail?id=2507362189","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2507362189?lang=zh_cn&edition=full","pubTime":"2025-01-30 22:31","pubTimestamp":1738247476,"startTime":"0","endTime":"0","summary":"北京时间2025年01月30日22时31分，Blackline, Inc.股票出现异动，股价急速上涨5.34%。Blackline, Inc.股票所在的软件服务行业中，整体跌幅为2.25%。其相关个股中，Alpha Modus Holdings, Inc.、Alpha Modus Holdings Inc C/Wts 13/12/2029 、Banzai International Inc C/Wts 14/12/2028 涨幅较大，Banzai International, Inc.、Alpha Modus Holdings, Inc.、Signing Day Sports, Inc.较为活跃，换手率分别为226.84%、158.87%、55.31%，振幅较大的相关个股有Alpha Modus Holdings, Inc.、Alpha Modus Holdings Inc C/Wts 13/12/2029 、讯鸟软件，振幅分别为20.13%、16.36%、9.22%。Blackline, Inc.公司简介：BlackLine Inc 致力于提供以软件即服务 形式交付的财务会计结算解决方案。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250130223116abbd4bfd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250130223116abbd4bfd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1815336091.USD","LU0757428866.USD","BK4023","BL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2507403496","title":"B of A Securities：上调BlackLine(BL.US)评级，由低于大市调整至买入评级, 目标价由50.00美元调整至75.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2507403496","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2507403496?lang=zh_cn&edition=full","pubTime":"2025-01-30 20:42","pubTimestamp":1738240955,"startTime":"0","endTime":"0","summary":"B of A Securities：上调BlackLine(BL.US)评级，由低于大市调整至买入评级, 目标价由50.00美元调整至75.00美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/01/30204247909594.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2507654435","title":"Blackline, Inc.盘中异动 下午盘股价大涨5.01%报64.81美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2507654435","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2507654435?lang=zh_cn&edition=full","pubTime":"2025-01-29 02:20","pubTimestamp":1738088457,"startTime":"0","endTime":"0","summary":"北京时间2025年01月29日02时20分，Blackline, Inc.股票出现波动，股价大幅上涨5.01%。截至发稿，该股报64.81美元/股，成交量39.189万股，换手率0.63%，振幅5.30%。Blackline, Inc.股票所在的软件服务行业中，整体涨幅为2.63%。Blackline, Inc.公司简介：BlackLine Inc 致力于提供以软件即服务 形式交付的财务会计结算解决方案。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501290220579875840e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501290220579875840e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4023","LU1815336091.USD","BL","LU0757428866.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2501662192","title":"Blackline, Inc.盘中异动 股价大跌5.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2501662192","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2501662192?lang=zh_cn&edition=full","pubTime":"2025-01-07 02:59","pubTimestamp":1736189972,"startTime":"0","endTime":"0","summary":"北京时间2025年01月07日02时59分，Blackline, Inc.股票出现波动，股价大幅跳水5.05%。Blackline, Inc.股票所在的软件服务行业中，整体涨幅为0.49%。其相关个股中，Arbe Robotics Ltd C/Wts 07/10/2026 、Nextplat Corp C/Wts 02/06/2027 、Aeye Inc C/Wts 30/09/2027 涨幅较大，Cerence Inc.、Arbe Robotics Ltd.、Intrusion Inc.较为活跃，换手率分别为137.78%、133.78%、84.88%，振幅较大的相关个股有Nextplat Corp C/Wts 02/06/2027 、Arbe Robotics Ltd C/Wts 07/10/2026 、Hub Cyber Security Ltd C/Wts 27/02/2028 ，振幅分别为156.48%、95.82%、70.00%。Blackline, Inc.公司简介：BlackLine Inc 致力于提供以软件即服务 形式交付的财务会计结算解决方案。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250107025932aba0c071&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250107025932aba0c071&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BL","LU1815336091.USD","LU0757428866.USD","BK4023"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2500917405","title":"百利天恒(688506.SH)：注射用BL-B01D1被药审中心纳入突破性治疗品种名单","url":"https://stock-news.laohu8.com/highlight/detail?id=2500917405","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2500917405?lang=zh_cn&edition=full","pubTime":"2025-01-02 17:08","pubTimestamp":1735808923,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百利天恒 发布公告，公司自主研发的创新生物药注射用BL-B01D1用于既往经含铂化疗及抗PD-1/PD-L1单抗治疗失败的复发性小细胞肺癌患者已被国家药品监督管理局药品审评中心纳入突破性治疗品种名单，近日已完成公示。BL-B01D1是公司自主研发的全球首创也是唯一进入临床阶段的靶向EGFR×HER3的双抗ADC。BL-B01D1正在中国和美国进行超过20项针对多种肿瘤类型的临床试验。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1232507.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","688506","BL","LU1815336091.USD","BK4023","LU0757428866.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2486396776","title":"百利天恒(688506.SH)：BL-M08D1(ADC)临床试验申请获得批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2486396776","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2486396776?lang=zh_cn&edition=full","pubTime":"2024-11-28 18:16","pubTimestamp":1732788963,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百利天恒(688506.SH)发布公告，公司于近日收到国家药品监督管理局(NMPA)正式批准签发的《药物临床试验批准通知书》,公司自主研发的创新生物药BL-M08D1(ADC)的药物临床试验获得批准。BL-M08D1是与BL-B01D1出自同一小分子技术平台、与BL-B01D1共享同一“连接子+毒素”平台的ADC药物，其适应症为复发或难治性血液系统恶性肿瘤和局部晚期或转移性实体瘤。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1217375.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","ADC","BK1576","BK1141","688506","03347","BK1583","BK4231","BK4080","BL","LU1815336091.USD","LU0757428866.USD","BK4023"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2484971548","title":"Blackline, Inc.2024财年第三财季实现净利润17.24百万美元，同比增加44.63%","url":"https://stock-news.laohu8.com/highlight/detail?id=2484971548","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2484971548?lang=zh_cn&edition=full","pubTime":"2024-11-17 00:04","pubTimestamp":1731773074,"startTime":"0","endTime":"0","summary":"11月17日，Blackline, Inc.公布财报，公告显示公司2024财年第三财季净利润为17.24百万美元，同比增加44.63%；其中营业收入为1.66亿美元，同比增加9.93%，每股基本收益为0.28美元。从资产负债表来看，Blackline, Inc.总负债12.98亿美元，其中短期债务3.98百万美元，资产负债比为1.31，流动比率为2.69。机构评级：截至2024年11月17日，当前有10家机构对Blackline, Inc.目标价做出预测，其中目标均价为63.20美元，其中最低目标价为50.00美元，最高目标价为81.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241117000559a23e07ee&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241117000559a23e07ee&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BL"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.blackline.com","stockEarnings":[{"period":"1week","weight":0.001},{"period":"1month","weight":0.0582},{"period":"3month","weight":-0.0162},{"period":"6month","weight":-0.0543},{"period":"1year","weight":-0.4009},{"period":"ytd","weight":-0.461}],"compareEarnings":[{"period":"1week","weight":-0.0197},{"period":"1month","weight":0.0122},{"period":"3month","weight":0.0269},{"period":"6month","weight":0.0748},{"period":"1year","weight":0.1553},{"period":"ytd","weight":0.1193}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"BlackLine, Inc.以BlackLine Systems, Inc之名成立于2001年5月。该公司已经创建了一个全面的基于云计算的软件平台，旨在为所有类型和规模的组织变革和现代化的会计和财务运作。他们的安全可扩展的平台支持关键会计流程，如财务结算，对账，公司间的会计和控制的保证等。通过引入软件来自动化这些流程并使其能够持续运行，他们授权客户提高其财务报告的完整性，提高效率并增强其运营的实时可见性。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.010267},{"month":2,"riseRate":0.4,"avgChangeRate":-0.029288},{"month":3,"riseRate":0.4,"avgChangeRate":-0.032085},{"month":4,"riseRate":0.5,"avgChangeRate":-0.004741},{"month":5,"riseRate":0.6,"avgChangeRate":0.013167},{"month":6,"riseRate":0.8,"avgChangeRate":0.025467},{"month":7,"riseRate":0.5,"avgChangeRate":0.007955},{"month":8,"riseRate":0.7,"avgChangeRate":0.03306},{"month":9,"riseRate":0.5,"avgChangeRate":-0.008436},{"month":10,"riseRate":0.6,"avgChangeRate":0.003005},{"month":11,"riseRate":0.7,"avgChangeRate":0.09203},{"month":12,"riseRate":0.3,"avgChangeRate":-0.011744}],"exchange":"NASDAQ","name":"Blackline Inc.","nameEN":"Blackline Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Blackline Inc.(BL)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Blackline Inc.(BL)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Blackline Inc.,BL,Blackline Inc.股票,Blackline Inc.股票老虎,Blackline Inc.股票老虎国际,Blackline Inc.行情,Blackline Inc.股票行情,Blackline Inc.股价,Blackline Inc.股市,Blackline Inc.股票价格,Blackline Inc.股票交易,Blackline Inc.股票购买,Blackline Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Blackline Inc.(BL)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Blackline Inc.(BL)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}